Back to News
Market Impact: 0.35
Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction
Source: fool.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Pfizer reported flat revenue of $16.6 billion as lower COVID and Prevnar sales were offset by growth in Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena. The company raised its full-year revenue and adjusted EPS guidance, though the article gives no revised figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PFE0.45
More News
- Pfizer hikes full-year outlook, taps company veteran as new CFO
- Pfizer earnings analysis: questions answered and next catalysts
- Stocks making the biggest moves midday: Apple, Palantir, Nvidia, Coinbase, Bloom Energy & more
- Stocks making the biggest moves premarket: Pfizer, Apple, Palantir, Zebra Technologies & more
- Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher
- Stock Movers: PFR, AAPL, BE (Podcast)